Hemab, working to build ‘ultimate clotting company,’ raises $157M series C for bleeding disorder ambitions
With a $157 million series C funding round, Hemab Therapeutics is looking to infuse innovation into the treatment landscape for rare and underserved bleeding disorders. The oversubscribed series C was…